Stockscreener 앱 받기
2.82
8.05%
0.21
시간 외 거래:
2.82
Mannkind Corp 주식(MNKD)의 최신 뉴스
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma - Investing.com
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock - MarketBeat
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's Why - MarketBeat
MannKind presents Afrezza data at diabetes conference - Investing.com
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - Yahoo Finance
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance
Vanguard Group Inc. Has $94.68 Million Holdings in MannKind Corporation $MNKD - MarketBeat
MannKind settles $36.3M convertible notes with cash, shares By Investing.com - Investing.com Canada
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Re - GuruFocus
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
MannKind Announces Settlement of Convertible Senior Notes - Yahoo Finance
Wedbush Lowers Price Target for MannKind (MNKD) While Maintainin - GuruFocus
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wedbush - MarketBeat
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets - Finviz
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
MannKind (NASDAQ:MNKD) Sets New 1-Year LowHere's What Happened - MarketBeat
MannKind (NASDAQ: MNKD) CFO adds 5,000 shares via stock purchase plan - Stock Titan
MannKind (MNKD) director adds 12,000 shares via Market Price Stock Purchase Plan - Stock Titan
MannKind (MNKD) director reports vesting of 45,025 performance-based stock options - Stock Titan
MannKind (MNKD) CEO gains stock and option vesting on milestones - Stock Titan
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade - MarketBeat
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook By Investing.com - Investing.com Canada
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook - Investing.com
RBC Capital downgrades MannKind stock rating on royalty concerns By Investing.com - Investing.com Canada
RBC Capital downgrades MannKind stock rating on royalty concerns - Investing.com
A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns - simplywall.st
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MannKind Corp. Hits New 52-Week Low at $2.94 Amid Declining Stock Performance - Markets Mojo
MannKind Corporation (MNKD): A Bull Case Theory - Finviz
MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About MannKind Corp (MNKD) - GuruFocus
MNKD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MNKD: RBC Capital Downgrades MannKind with Price Target Cut by 5 - GuruFocus
What's Going On With MannKind Stock Friday? - Benzinga
Wells Fargo Lowers MNKD Price Target to $7.00, Maintains Overwei - GuruFocus
MNKD: HC Wainwright & Co. Lowers Price Target to $8.00 | MNKD St - GuruFocus
Reassessing MannKind (MNKD) After Sharp Recent Share Price Declines - Yahoo Finance
Why MannKind Stock Tumbled on Thursday - Yahoo Finance
MannKind at Oppenheimer Conference: Strategic Insights for 2026 - Investing.com
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
Earnings call transcript: MannKind Q4 2025 results show mixed performance By Investing.com - Investing.com South Africa
Earnings call transcript: MannKind Q4 2025 results show mixed performance - Investing.com Nigeria
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead By Investing.com - Investing.com South Africa
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead - Investing.com
MannKind hits 52-week low on Q4 earnings miss (MNKD:NASDAQ) - Seeking Alpha
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 - ChartMill
Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M - marketscreener.com
MANNKIND ($MNKD) Releases Q4 2025 Earnings - Quiver Quantitative
MannKind: Fourth Quarter Earnings Overview - Bitget
MannKind: Q4 Earnings Snapshot - marketscreener.com
MANNKIND CORP SEC 10-K Report - TradingView
MannKind Corporation Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Caledonian Record
MannKind Earnings Review: Q4 Summary - Benzinga
MannKind (NASDAQ:MNKD) Reaches New 1-Year LowShould You Sell? - MarketBeat
MannKind Corp stock hits 52-week low at $3.36 - Investing.com India
United Therapeutics Rival Inhaler Tests MannKind Valuation And Royalty Outlook - simplywall.st
MNKD MannKind (NASDAQ): Shares slide 36.82% to $3.50 pre-earnings, catalyst to watch - Meyka
MannKind Corp stock hits 52-week low at $3.36 By Investing.com - Investing.com Australia
MannKind stock plummets after partner United Therapeutics unveils new 'category killer product' - MSN
MannKind (MNKD) Shares Plummet Amid United Therapeutics Announcement - GuruFocus
1.57%
0.40%
자본화:
|
볼륨(24시간):